ID 112381
Author
Li, Huizi Keiko National Institutes for Quantum and Radiological Science and Technology|Chiba University|Japan Society for the Promotion of Science
Sugyo, Aya National Institutes for Quantum and Radiological Science and Technology
Tsuji, Atsushi B. National Institutes for Quantum and Radiological Science and Technology
Morokoshi, Yukie National Institutes for Quantum and Radiological Science and Technology
Minegishi, Katsuyuki National Institutes for Quantum and Radiological Science and Technology
Nagatsu, Kotaro National Institutes for Quantum and Radiological Science and Technology
Kanda, Hiroaki Japanese Foundation for Cancer Research
Harada, Yosuke OncoTherapy Science Inc.
Nagayama, Satoshi Japanese Foundation for Cancer Research
Nakamura, Yusuke The University of Chicago
Higashi, Tatsuya National Institutes for Quantum and Radiological Science and Technology
Hasegawa, Sumitaka National Institutes for Quantum and Radiological Science and Technology
Keywords
α-particle
β-particle
frizzled homolog 10
radioimmunotherapy
synovial sarcoma
Content Type
Journal Article
Description
Synovial sarcoma (SS) is a rare yet refractory soft‐tissue sarcoma that predominantly affects young adults. We show in a mouse model that radioimmunotherapy (RIT) with an α‐particle emitting anti‐Frizzled homolog 10 (FZD10) antibody, synthesized using the α‐emitter radionuclide astatine‐211 (211At‐OTSA101), suppresses the growth of SS xenografts more efficiently than the corresponding β‐particle emitting anti‐FZD10 antibody conjugated with the β‐emitter yettrium‐90 (90Y‐OTSA101). In biodistribution analysis, 211At was increased in the SS xenografts but decreased in other tissues up to 1 day after injection as time proceeded, albeit with a relatively higher uptake in the stomach. Single 211At‐OTSA101 doses of 25 and 50 μCi significantly suppressed SS tumor growth in vivo, whereas a 50‐μCi dose of 90Y‐OTSA101 was needed to achieve this. Importantly, 50 μCi of 211At‐OTSA101 suppressed tumor growth immediately after injection, whereas this effect required several days in the case of 90Y‐OTSA101. Both radiolabeled antibodies at the 50‐μCi dosage level significantly prolonged survival. Histopathologically, severe cellular damage accompanied by massive cell death was evident in the SS xenografts at even 1 day after the 211At‐OTSA101 injection, but these effects were relatively milder with 90Y‐OTSA101 at the same timepoint, even though the absorbed doses were comparable (3.3 and 3.0 Gy, respectively). We conclude that α‐particle RIT with 211At‐OTSA101 is a potential new therapeutic option for SS.
Journal Title
Cancer Science
ISSN
13497006
Publisher
Japanese Cancer Association
Volume
109
Issue
7
Start Page
2302
End Page
2309
Published Date
2018-06-27
Rights
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Institute of Advanced Medical Sciences